Summary The haemorheological agent pentoxifylline (PTX) has been shown to improve the relative perfusion and oxygenation of subcutaneous tumours in the mouse. In order to establish whether this effect is dependent on the site of tumour growth, we have looked at changes in the distribution of the cardiac output (COD) to the murine NT carcinoma grown either intradermally (i.d.), intramuscularly (i.m.), on the wall of the caecum, or in all three sites, following i.p. administration of 50 mg kg-' PTX. In animals bearing a single tumour, PTX treatment significantly increases the COD to tumours located in the caecum, but has no significant effect on the COD to those located in the i.d. or i.m. sites. If all three tumours are present in a single animal, the COD to all three tumours is significantly enhanced by PTX. This appears to reflect the presence of the caecum tumour and does not appear to relate to changes in tumour size or to the haematocrit (HCT) of the blood. We propose that this site dependency implies that a significant increase in blood viscosity only occurs in animals with tumours located in specific sites. Therefore, the potential radiosensitising capability of PTX is highly dependent on tumour location.
Tumour perfusion is governed by the arteriovenous pressure gradient across the vascular bed and by the resistance that the blood encounters within the microvasculature. Resistance to flow arises from the geometric structure of the blood vessels and from the viscosity of the perfusing blood. Unlike normal tissues, the heterogeneity and transient nature of the tumour microvasculature gives rise to regions where blood flow becomes sluggish and may even occur in a retrograde direction (see Jain, 1988, for review) . This results in haemoconcentration within the tumour, thus increasing the viscosity of the blood as it passes through the tumour microcirculation. Since the delivery of therapeutic drugs to tumours would be enhanced by an increase in tumour perfusion rate, the benefits of reducing blood viscosity, and therefore the flow resistance, are self evident.
The methyl xanthine derivative, pentoxifylline (PTX), a drug used clinically for the treatment of intermittent claudication and peripheral vascular disease, is known to lower blood viscosity both directly, by increasing the deformability of erythrocytes (Dormandy et al., 1981; Carr & Hauge, 1990) , and indirectly, by preventing the formation of clusters of red cells, or rouleaux, via the stimulation of fibrinolysis resulting from the release of prostacyclin from the endothelial cells (Jarrett et al., 1977; Muller, 1979; Matzky et al., 1982) . By reducing the rigidity of the red cells, their passage through small arterioles and capillaries, such as those present in the tumour microcirculation, is improved.
Whilst the treatment of peripheral vascular disorders is the principal use for PTX, its multifaceted haemorheological properties have resulted in it being used in numerous therapeutic trials, including treatment for cerebrovascular disease, ischaemic heart disease and sickle cell disease (see Ward & Clissold, 1987, for review) . Its place as a potential radiosensitiser for cancer therapy has been investigated in a number of studies on subcutaneous murine tumours, in which PTX treatment was shown to improve tumour perfusion and oxygenation, as well as enhancing growth delay following Xirradiation (Lee et al., 1992; Song et al., 1992; Honess, 1991) .
Recent studies have demonstrated that tumour site is an important determinant of tumour response to various vasoactive agents and to induced anaemia (Hirst et al., 1991; Hirst et al., 1993; Sensky et al., in press). We therefore wished to determine if the tumour response to PTX was also site dependent. In this study, we have compared the effects of PTX on the distribution of the cardiac output (COD) to tumours implanted in one or each of three sites, located intradermally (i.d.), intramuscularly (i.m.), or on the wall of the caecum. The relative effectiveness of PTX following an increase in tumour size or a reduction in haematocrit is also investigated.
Methods

Animals and tumours
The NT carcinoma (CaNT), a transplantable mammary adenocarcinoma, was used in syngeneic CBA male 8-weekold mice in all experiments. The transplants in the three sites were staggered so that they all reached a treatable size on the same day.
A single suspension of tumour cells was prepared in physiological saline. Three to 5 x I05cells were inoculated intradermally (i.d.) on the back in a volume of 50 ;l. Three days post-transplant, a 0.5-1.0mm3 tumour fragment was applied to the surface of the caecum using the tumour patch technique described by Hirst et al. (1993) (Honess, 1991) . PTX was administered 15 min prior to the measurement of relative perfusion.
Measurement of the relative distribution of the cardiac output The COD to each tumour and to several normal tissues, including the gastrocnemius muscle from the contralateral leg to the site of the i.m. tumour, the liver, the kidney, the spleen, the gut and the tail, was measured 15 min after treatment with PTX, using the 86Rb extraction technique (Sapirstein, 1958 
Results
Tumour size and haematocrit A significant increase in the weight of each tumour was recorded between the two days on which COD was measured. On both days, the tumour size of single tumour-bearing animals was similar to the size of the same tumour in those animals in which all three tumours were present (Table  I) .
Reductions in haematocrit (HCT) were closely related to increases in total tumour burden (Figure 1; (Figure 2) .
The only consistent effect of PTX treatment on the COD to the other tissues excised was the increased perfusion of the spleen (Figure 2 (Figure 3) .
In general, the COD to each tumour was lower if all three tumours were present (Table II Table 11 The relative distribution of the cardiac output (COD) to intradermal (i.d.), intramuscular (i.m.) and caecum tumours in untreated animals and in animals treated with pentoxifylline (+ PTX (Jain, 1988 (Aviado & Porter, 1984; Dion et al., 1989) . The anti-platelet action of PTX, mediated by the release of prostacyclin from the endothelial cells is also well documented (Gastpar et al., 1978; Ambrus et al., 1979; Weithmann, 1981) . In addition, the release of prostacyclin stimulates fibrinolysis (Jarrett et al., 1977 For PTX to exert an effect we are assuming that the viscosity must be raised, since there is no direct evidence that PTX affects the in vivo blood viscosity under normal conditions. Attempts to measure the blood viscosity proved to be unreliable, due to the time lapse between sampling and measurement and the change in the environmental conditions of the blood, a phenomenon that has been experienced before (Hirst & Wood, personal communication) . However, the COD to the spleen may provide a means of assessing how blood viscosity was modified.
The spleen acts as a sieve to trap aged red blood cells for cellular degradation, making it an organ resistant to the passage of erythrocytes. In this respect, the spleen can be regarded as a highly sensitive 'test' organ for detecting any changes in blood viscosity, i.e., if PTX treatment increases the COD to the spleen, then the viscosity of the blood prior to PTX administration must have been greater than normal. This may even prove to be a highly accurate means of detecting changes in in vivo blood viscosity. Therefore, the increased COD to the spleen in all animals following PTX treatment (Figure 2) suggests that the viscosity was raised whenever the tumour was present. The fact that the COD to the tumours located in the i.d. and i.m. sites was not improved by PTX suggests that the viscosity was not increased sufficiently to elicit a PTX mediated response. Indeed, the splenic COD was increased to 183 ± 14% control values in animals bearing caecum tumours, whilst it was only increased to 153 ± 17% and 147 ± 32% control values in the i.d. and i.m. sites, respectively (Figure 2 ). This argument must, however, remain speculative in the absence of further data.
The increased COD to all three tumours following PTX treatment in animals bearing tumours located in all three sites appears to confuse the issue. It may be that local changes in viscosity of blood passing through the caecum tumour has an effect on the viscosity of the blood as a whole, so that if viscosity is raised sufficiently in one site, PTX will be equally effective in other locations. This hypothesis is supported by the data for the modification of splenic blood flow. Alternatively, whilst tumour weight may not influence the effects of PTX in single tumour bearing animals, an increase in tumour burden arising from more than one tumour site may have profound effects on the rheological properties of the blood of these animals. Thus, when assessing the potential of PTX as a radiosensitising agent it is important to realise that its effectiveness may be highly dependent on the location of the tumour to be treated. ---.-j Reports that the COD to RIF-1 tumours and the oxygenation of FSaII and SCK tumours implanted in subcutaneous sites are enhanced following PTX treatment (Honess, 1991; Lee et al., 1992; Song et al., 1992) suggests that the tumour response to PTX is also tumour type dependent. This sitedependency could have important implications for the use of PTX in the treatment of cancer.
